Company business introduction

CanalLotus Biotech is the bridge between global pharmaceutical innovation and China. This overview film introduces two partnership models: license-in and co-development for assets with global potential, and an international CRDMO path from early development through commercial supply. Capabilities rest on three platforms—peptides (including GLP-1), high-potency oncology, and lipid-based drug delivery—so partners can move from asset to supply with one connected team. Backed by more than a decade in clinical drug import and export, CanalLotus is built for long-term collaboration.